1 Abstract
Background Molecular testing for SARS-CoV-2 continues to suffer from delays and shortages. Antigen tests have recently emerged as a viable alternative to detect patients with high viral loads, associated with elevated risk of transmission. While rapid lateral flow tests greatly improved accessibility of SARS-CoV-2 detection in critical areas, their manual nature limits scalability and suitability for large-scale testing schemes. The Elecsys® SARS-CoV-2 Antigen assay allows antigen immunoassays to be carried out on fully automated high-throughput serology platforms.
Methods A total of 3139 nasopharyngeal and oropharyngeal swabs were collected at 3 different testing sites in Germany. Swab samples were pre-characterized by RT-qPCR and consecutively subjected to the antigen immunoassay on either the cobas e411 or cobas e801 analyzers.
Results Of the tested respiratory samples, 392 were PCR positive for SARS-CoV-2 RNA. Median concentration was 2.95×104 (interquartile range [IQR] 5.1×102—3.5×106) copies/mL. Overall sensitivity and specificity of the antigen immunoassay were 60.5% (95% confidence interval [CI] 55.5–65.4) and 99.9% (95% CI 99.6–100), respectively. A 93.7% (95% CI 89.7–96.5) sensitivity was achieved at a viral RNA concentration ≥104 copies/mL (∼cycle threshold (Ct) value<29.9).
Conclusion The Elecsys SARS-CoV-2 Antigen assay reliably detected patient samples with viral loads of 10,000 copies/mL and higher. It thus represents a viable high-throughput alternative for pre-screening of patients, or in situations where PCR testing is not readily available.
Competing Interest Statement
Tanja Schneider, Kathrin Schönfeld, and Tina Laengin are employees of Roche Diagnostics GmbH. Marc Lütgehetmann has received speaker's honoraria and related travel expenses from Roche Diagnostics. Elena Riester has received speaker's honorarium from Roche. Stojan Perisic, Flaminia Olearo, Matthias F. Bauer and Dominik Nörz have no conflicts to report. This study was funded by Roche Diagnostics GmbH (Mannheim, Germany). Medical writing support, under the direction of the authors, was provided by Tina Patrick (Elements Communications Ltd, Westerham, Kent, UK) and was funded by Roche Diagnostics International Ltd, Rotkreuz, Switzerland.
Funding Statement
This study was funded by Roche Diagnostics GmbH (Mannheim, Germany). Medical writing support, under the direction of the authors, was provided by Tina Patrick (Elements Communications Ltd, Westerham, Kent, UK) and was funded by Roche Diagnostics International Ltd, Rotkreuz, Switzerland.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was conducted in accordance with applicable regulations, the study protocol provided by Roche Diagnostics, and the principles of the Declaration of Helsinki. The use of anonymized remnant samples material was approved by ethical review committees prior to study initiation (ethics committee names and approval numbers: Ethik-Kommission bei der Landesärztekammer Baden-Württemberg; F-2020-154 [Stuttgart]; Ethik-Kommission der Ärztekammer Hamburg: WF-184/20 [Hamburg]; Ethik-Kommission bei der Landesärztekammer Rheinland-Pfalz: 2020-15449[Ludwigshafen]).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Qualified researchers may request access to individual patient level data through the clinical study data request platform (https://vivli.org/). Further details on Roche's criteria for eligible studies are available here: https://vivli.org/members/ourmembers/. For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here: https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm
